Key facts
- myotwin’s last known valuation is $21.6M (Sep 2025).
- It has raised $870K; the latest was Seed Round ($4.1M) in Sep 2025.
- Notable investors include BioIntelligence, SNIC Accelerator.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for myotwin
- ·The full record, as it builds
Funding rounds
No funding rounds for myotwin are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About myotwin
Developer of a technology and process intended to analyze induced pluripotent stem cells-derived macroscopic human myocard in unprecedented detail. The company is based on organoids of the human heart muscle and innovative methods that provide reproducible results in detail for a variety of use cases, such as drug testing, enabling clients to increase development speed and de-risk their pre-clinical stage while simultaneously reducing the need for animal testing.
- Sector
- Healthcare
- HQ
- Gottingen, Germany
- Founded
- 2022
- Employees
- 9
- Website
- myotwin.com/
- Ownership
- Privately Held (backing)
myotwin doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in myotwin shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on myotwin in its N-PORT filings yet. We sweep new filings monthly.